Argenx SE 6-K, filed May 5, 2023
Argenx SE (ARGX)
About this 6-K
Argenx SE filed this 6-K on May 5, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2023
Commission File Number: 001-38097
ARGENX SE
(Translation of registrant’s name into English)
Laarderhoogtweg 25
1101 EB Amsterdam, the Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
On May 3, 2023, argenx SE (the “Company”) issued a press release and the voting results from its Annual General Meeting of Shareholders held on May 2, 2023, copies of which are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.
The information contained in this Current Report on Form 6-K, including Exhibit 99.1 and Exhibit 99.2, is incorporated by reference into the Company’s Registration Statements on Forms F-3 (File No. 333-258251) and S-8 (File Nos. 333-225375 and 333-258253).
EXHIBITS
| Exhibit | Description | |
| 99.1 | Press Release dated May 3, 2023 | |
| 99.2 | Voting Results from the Annual General Meeting of Shareholders held on May 2, 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ARGENX SE | ||
| Date: May 5, 2023 | By: | /s/ Hemamalini (Malini) Moorthy |
| Hemamalini (Malini) Moorthy | ||
Exhibit 99.1
argenx announces results of Annual General Meeting of Shareholders
May 3, 2023
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its annual general meeting of shareholders held yesterday.
All items on the agenda received a majority of votes in favor except for agenda item 3 (advisory non-binding vote on the 2022 remuneration report).
As part of the approved resolutions:
| · | The company's annual report and annual accounts for the financial year ending December 31, 2022 were approved; |
| · | Don deBethizy has been re-appointed as non-executive director to the Board of Directors for a term of 2 years; |
| · | The Board of Directors was authorized to issue shares and grant rights to subscribe for shares in the share capital of the company for up to 10% of the outstanding share capital at the date of the meeting and for a period of 18 months from the meeting; and |
| · | Deloitte Accountants B.V. has been appointed as the Company's auditor for the 2023 financial year. |
The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and- only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and UK, and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit https://www.argenx.com/ and follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Erin Murphy
emurphy@argenx.com
Investors:
Beth DelGiacco
bdelgiacco@argenx.com
Exhibit 99.2
Annual general meeting of argenx SE May 2, 2023 – Voting results
| Total number of outstanding shares at the record date. | 55,685,883 | |||
| Total shares present or represented at the AGM. | 46,781,165 | |||
| Percentage represented share capital at AGM. | 84.01 | % | ||
| Total valid votes at AGM. | 46,781,165 |
| Agenda Item |
Resolution | |||
| 3 | Advisory vote on the 2022 remuneration report. | |||
| Votes for | 20,460,533 | (44.14%) | ||
| Votes against | 25,890,803 | (55.86%) | ||
| Abstained | 429,829 | |||
| 4b | Adoption of the 2022 annual accounts. | |||
| Votes for | 45,102,996 | (99.48%) | ||
| Votes against | 1,164,867 | (0.52%) | ||
| Abstained | 364,908 | |||
| 4d | Allocation of losses of argenx SE in the financial year 2022 to the retained earnings of argenx SE. | |||
| Votes for | 46,488,519 | (99.72%) | ||
| Votes against | 129,408 | (0.28%) | ||
| Abstained | 163,238 | |||
| 4e | Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2022. | |||
| Votes for | 45,783,436 | (97.87%) | ||
| Votes against | 458,681 | (2.13%) | ||
| Abstained | 539,048 | |||
| 5 | Re-appointment of Don deBethizy as non-executive director for a period of 2 years. | |||
| Votes for | 32,615,544 | (69.96%) | ||
| Votes against | 14,002,411 | (30.04%) | ||
| Abstained | 163,210 | |||
Annual general meeting of argenx SE May 2, 2023 – Voting results
| 6 | Authorization of the board of directors to issue shares and grant rights to subscribe for shares in the share capital of argenx SE up to a maximum of 10% of the outstanding capital at the date of the general meeting, for a period of 18 months from the annual general meeting and to limit or exclude statutory pre-emptive rights, if any. | |||
| Votes for | 46,383,722 | (99.49%) | ||
| Votes against | 235,663 | (0.51%) | ||
| Abstained | 161,780 | |||
| 7 | Appointment of Deloitte Accountants B.V. as statutory auditor for the 2023 financial year. | |||
| Votes for | 46,605,961 | (99.97%) | ||
| Votes against | 12,535 | (0.03%) | ||
| Abstained | 162,669 | |||